Prevention of corticosteroid-induced osteoporosis by alfacalcidol.

We studied the effect of alphacalcidol (1-alpha-hydroxycholecalciferol) on bone metabolism in patients who were placed on glucocorticoid therapy. We selected 41 women (age: 32-52 yrs) who were recently diagnosed with systemic lupus erythematodes, multiple sclerosis, rheumatoid arthritis or asthma bronchiale. Patients did not have other disease or take drugs known to influence bone metabolism.

[Bone mineral content in osteogenesis imperfecta].

Bone mineral content (BMC) in the radius of 23 osteogenesis imperfecta (OI) patients (1-26 yr) was measured with SPA technique. Comparing the values of OI type I. patients with that of type III.

[Ultrastructural and histological studies on type I osteogenesis imperfecta].

The results of 3 bone biopsies in patients with Sillence I. type of osteogenesis imperfecta are described. The biopsy material was examined with light microscope histomorphometric and various electron microscopic methods.

[A new treatment possibility for osteoporosis with osteochin (ipriflavone) tablets].

It was found as a result of preclinical experimental examinations, performed in Hungary and Japan that Ipriflavone stimulates calcitonin secretion through increasing the oestrogene effect. Its effect of hindering bone resorption works presumably also this way. Authors report on experiences and results gained in 408 treatment years of 114 primary and secondary osteoporotic patients.